Rua Life Sciences Share Discussion Threads

[z1co] 05/4/2024 10:48

Looking very strong

[purple11] 05/4/2024 10:48

i wouldnt believe a word ZICO says.he'll be long gone as soon as his stock falls 5%

hes a proven liar with a string of horrific calls to his name.

PPP PIP OBI HE1 all his calls failed spectacularilly in the last couple of months.

hes a ramper and a liar

BEWARE!

[z1co] 05/4/2024 10:47

Moving up nicely

[z1co] 05/4/2024 10:47

Another nasty email from the troll:

===================

everywhere you go everywhere you go

purple11 to me 05 Apr 2024 09:00:30

you were too stupid to accept a truce now im going to warn posters of you EVERY SINGLE TIME YOU POST.

OKAY?

==================

[z1co] 05/4/2024 10:46

!FOLLOWFEED

[trotterstrading] 05/4/2024 10:18

Really strong update, expecting a rerate over the next week or so

[citys2874] 05/4/2024 09:52

Great morning and start for RUA and SAAS ....both looking to breakout massively.....may see a major bounce up ....nice!!

[z1co] 05/4/2024 09:48

Apologies to all lth.

This nasty and very sad troll is doing this because he lost around £2500 in PPP and he blames me.The idiot thinks it's my fault.

He probably is a sad loser in life

[purple11] 05/4/2024 09:41

i wouldnt believe a word ZICO says.he'll be long gone as soon as his stock falls 5%

hes a proven liar with a string of horrific calls to his name.

PPP PIP OBI HE1 all his calls failed spectacularilly in the last couple of months.

hes a ramper and a liar

BEWARE!

[z1co] 05/4/2024 09:38

At last some excellent news from the company.

Shares will steadily rise again and certainly worth a lot more than 20p.

[parob] 05/4/2024 09:35

"Our material has exceeded expectations, demonstrating remarkable durability and energy efficiency compared to market-leading valves."I am focussing on current market cap against the size of the market."The global Heart Valves Market size was valued at USD 6.58 billion in 2018 and is projected to reach USD 15.98 billion by 2026"hTTps://www.fortunebusinessinsights.com/amp/industry-reports/heart-valves-market-101183

[harrogate] 05/4/2024 09:30

And they better not have signed a commercial agreement as that should be so material that it would need to be announced and should get us flying. Unless they do another one with no cash like Corcym.

[harrogate] 05/4/2024 09:25

I think that is reading too much into the wording. They are partners as they have an MTA in place

[parob] 05/4/2024 09:20

Just one decent commercial deal and the market cap is worth a lot more than current £6M that's for sure.

[controlledmadness] 05/4/2024 09:16

No mention of the Stent test.

[bones] 05/4/2024 09:16

I was intrigued by this wording about the MTA:

“……;….is currently being tested by this partner”.

Are they already a partner? A party to a testing agreement maybe, but a partner seems to imply a stronger relationship.

[parob] 05/4/2024 09:11

This being key:"the Company is pleased to announce that it has succeeded in securing the initial development stages of a significant contract with a global enterprise."Looking forward to hearing further updates on this.

[blackhorse23] 05/4/2024 09:07

https://www.londonstockexchange.com/news-article/APH/full-year-trading-update/16307097

[parob] 05/4/2024 08:59

Very good update imo. Plenty of cash/time to get sone commercial deals over the line. Speculation alone could drive this higher. Business Update RUA Life Sciences (AIM: RUA), the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon™), today provides an update on trading for the financial year ending 31 March 2024 and developments since the successful fundraise in December 2023.TradingThe first half of the financial year was impacted by operational issues, resulting in the delayed shipment of products from the Contract Manufacturing business. As anticipated, the revenue shortfall experienced during H1 has been fully compensated by a strong H2 performance. As a result, the Company expects to report, subject to audit, FY24 revenue of £2.2 million, which is in line with market expectations. The Company is pleased to announce that the recovery in revenues has not been at the cost of gross margins, and it is anticipated that reported margins will exceed expectations. The Group has focussed on cost control throughout the year. These rigorous measures are expected to result in operating costs of £3.4 million, approximately £0.2 million below market expectations for the year.Cash PositionStrong cost management, together with the anticipated recovery in trading during the second half, means the Company remains financially resilient, with a strong balance sheet and a cash position of approximately £4.0m. Despite challenging trading conditions, these achievements underscore the Group's resilience and adeptness in financial and operational management.Business DevelopmentSignificant efforts have been focussed on business development activities as part of the Group's strategy to reach profitability in the short term. It has been the strategy to seek to grow the scale of contract manufacturing, and the Company is pleased to announce that it has succeeded in securing the initial development stages of a significant contract with a global enterprise. This contract represents a major milestone on the route to doubling revenues for the contract manufacturing division once fully operational. Initial development work under this contract has commenced, with an initial purchase order valued at £100,000 already received.Additionally, as announced on 20 December 2023, the Company has successfully entered into a Material Transfer Agreement (MTA) with a global Heart Valve company. The Group's composite material has been delivered and is currently being tested by this partner. The non-calcific nature of Elast-Eon, together with the tear resistance of the novel composite (up to two times improvement over current materials), positions RUA as a leader in developing next-generation alternative leaflet material resistant to Structural Valve Degeneration (SVD). The Company is confident that these results will be of significant interest to other prospective partners and is actively exploring additional potential partnerships.Bill Brown, Chairman of RUA Life Sciences, stated: "Trading results for FY24 represent a meaningful step in delivering on the Group's strategy outlined in November, and the efforts to focus the business on growth are showing promise."Commenting on the Contract Manufacturing success, Bill added:"Securing this contract underscores RUA's expertise in implantable fabrics and moves us closer to profitability. It is our first major contract since the acquisition of RUA Medical Devices in 2020 and supports our belief that there are significant market opportunities in this area."Bill further elaborated on the heart valve composite by stating:"Our material has exceeded expectations, demonstrating remarkable durability and energy efficiency compared to market-leading valves. We are actively seeking partnerships to leverage these compelling results. RUA believes that these outstanding results in preclinical and bench studies are a result of the unique combination of RUA's expertise in medical fabrics and the biostability of Elast-Eon"

[letsbuy1] 04/4/2024 22:15

15/16p tmoz

[nik7907] 04/4/2024 21:27

Definite pump and dump imo. Lse site is full of it.

[harrogate] 04/4/2024 19:18

Always a joy to get new posters

[letsbuy1] 04/4/2024 19:04

Placing hahahha are you some kind of. D. I C K. Stop lying and putting S. H. I. T on here. There fully funded for. Years you. C. U. N. T after the massive raise at Xmas
What a. P. R. I. C K

[blackhorse23] 04/4/2024 18:56

Require placing in here & no money in bank. Switched to APH [LSE] , an excellent profitable health care company